Comprehensive 2025 Lumbosacral Radicular Pain Market Overview: Trends, Forecasts, and Growth Drivers

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Lumbosacral Radicular Pain Market Through 2025?
The market for lumbosacral radicular pain has seen significant growth in the past few years. It is predicted to increase from $0.91 billion in 2024 to $0.97 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 6.2%. This previous growth can be attributed to factors such as an increased occurrence of lower back disorders, an aging population with spinal problems, the rise of sedentary lifestyles and improper posture, greater demand for pain alleviation therapies, and heightened awareness regarding early detection and treatment.

What's the Projected Size of the Global Lumbosacral Radicular Pain Market by 2029?
The market size for lumbosacral radicular pain is projected to experience significant expansion within the next couple of years, with an estimation of reaching $1.21 billion by 2029, with an annual growth rate of 5.8%. This projected rise during the forecasted period is believed to be due to advancements in pain management technologies, a rising emphasis on non-opioid treatment choices, amplified funds in spinal studies and innovations, growing demand for outpatient and less invasive procedures, and increased availability of healare services in upcoming markets. Key trends observed during the forecast period are the progression in less invasive surgical methods, the discovery of targeted anti-inflammatory drugs, the breakthrough in wearable pain management gadgets, enhanced imaging for identifying nerve roots, and invention in personalized care plans making use of patient-specific information.

View the full report here:
https://www.thebusinessresearchcompany.com/report/lumbosacral-radicular-pain-global-market-report

Top Growth Drivers in the Lumbosacral Radicular Pain Industry: What's Accelerating the Market?
The growth of the lumbosacral radicular pain market is expected to be fuelled by the rising prevalence of degenerative spinal conditions. These conditions are a set of disorders caused by the spine's prolonged wear and tear over time. The growth in these spinal conditions is attributed to aging populations and lifestyle factors that enhance the likelihood of spinal degradation and nerve constriction, hence heightening the need for diagnosis and treatment. Lumbosacral radicular pain aids in pinpointing the underlying degenerative spinal disorders by demonstrating nerve root irritation or constriction, leading to comprehensive clinical assessment and treatment. For example, the University of Sydney, a public university in Australia, projected in May 2023 that by 2050, over 800 million people globally will experience back pain. Consequently, the rising occurrence of degenerative spinal conditions is contributing to the expansion of the lumbosacral radicular pain market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24591&type=smp

What Trends Will Shape the Lumbosacral Radicular Pain Market Through 2029 and Beyond?
Leading corporations in the lumbosacral radicular pain market are prioritizing the development of minimally invasive neuromodulation therapies, like small and rechargeable spinal cord stimulation (SCS) systems, to improve pain control and patient comfort. These compact spinal cord stimulation systems are implantable devices that administer electrical stimulation to the spinal cord, blocking pain signals, offering extended battery life, and providing non-invasive treatment alternatives. As an example, in December 2022, Abbott Laboratories, a healare company based in the United States, introduced the Eterna spinal cord stimulation system, employing advanced BurstDR therapy for efficient relief from chronic pain. The system uses cutting-edge rechargeable battery technology that significantly prolongs the interval between charges, thereby reducing patient inconvenience. It employs unique stimulation patterns, like BurstDR, which simulate natural nerve signals for more efficient and durable pain relief. The device is MRI-compatible and enables patients to have full-body scans safely without having to remove the device. The design of the system anticipates future enhancements, ensuring patients reap the benefits of progressing technological advancements without the need for further surgeries.

What Are the Main Segments in the Lumbosacral Radicular Pain Market?
The lumbosacral radicular pain market covered in this report is segmented -

1) By Treatment Type: Pharmacological Treatment, Non-Pharmacological Treatment, Interventional Procedures
2) By Route Of Administration: Oral, Topical, Injectable, Implantable
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By End User: Hospitals, Specialty Clinics, Rehabilitation Centers, Homecare Settings

Subsegments:
1) By Pharmacological Treatment: Nonsteroidal Anti-Inflammatory Drugs, Opioids, Anticonvulsants, Antidepressants, Muscle Relaxants, Corticosteroids
2) By Non-Pharmacological Treatment: Physical Therapy, Exercise And Rehabilitation Programs, Chiropractic Care, Acupuncture, Cognitive Behavioral Therapy, Heat And Cold Therapy
3) By Interventional Procedures: Epidural Steroid Injections, Radiofrequency Ablation, Nerve Root Blocks, Spinal Cord Stimulation, Minimally Invasive Decompression, Intrathecal Drug Delivery Systems

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=24591&type=smp

Which Top Companies are Driving Growth in the Lumbosacral Radicular Pain Market?
Major companies operating in the lumbosacral radicular pain market are Pfizer Inc., Johnson & Johnson Services Inc., Abbott Laboratories, Novartis AG, Medtronic plc, Eli Lilly and Company, Boston Scientific Corporation, Vertex Pharmaceuticals, Biotronik, Nevro Corp., Sorrento Therapeutics, Scilex Holding Company, ProMed Pharma, SPR Therapeutics, Saluda Medical Pty Ltd., Eliem Therapeutics, Cephalon Inc., Semnur Pharmaceuticals Inc., Nalu Medical Inc., Sollis Therapeutics Inc.

Which Regions Will Dominate the Lumbosacral Radicular Pain Market Through 2029?
North America was the largest region in the lumbosacral radicular pain market in 2024. The regions covered in the lumbosacral radicular pain market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24591

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.